For all patients who enroll into this study, study visits and serial measurements of safety and efficacy will be performed on a monthly basis for the first 12 months then on a 2-months basis thereafter. Tumor response, including progressive Disease, will be assessed according to the IMWG criteria. The severity of Adverse Events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. In this study, a central laboratory will analyze serum and urine protein electrophoresis tests (myeloma [M]-protein levels), serum and urine immunofixation studies (CHRU Lille). FISH cytogenetic will be performed in Nantes for all patients in the study.